Randomized Phase II Study of Pevonedistat Plus Azacitidine vs Azacitidine: Post Hoc Analysis in Higher-Risk MDS

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting

Addition of pevonedistat to azacitidine significantly prolonged EFS, with a trend for extended OS and evidence of activity among patients with poor prognostic markers (eg, TP53).

Format: Microsoft PowerPoint (.ppt)
File Size: 311 KB
Released: December 14, 2020


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bristol-Myers Squibb
Epizyme Inc.
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Downloadable slides from a Clinical Care Options (CCO) video on treatment strategies for patients with lower risk myelodysplastic syndrome (MDS)

Rami S. Komrokji, MD Released: January 15, 2021

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Brief expert video from Clinical Care Options (CCO) on recommended treatment strategies for patients with lower-risk myelodysplastic syndrome (MDS)

Rami S. Komrokji, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 15, 2021 Expired: January 14, 2022

Expert answers to clinician questions on current challenges in managing patients with myelodysplastic syndromes (MDS), from Clinical Care Options (CCO)

Guillermo Garcia-Manero, MD Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Released: January 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.